Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
145 pending office actions • 49 art units • 116 examiners • 1 of 145 (1%) have an AI response strategy ready • 162 patents granted in the last 365 days
Regeneron Pharmaceuticals Inc. currently has 144 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 117 distinct examiners, which is a smaller number than the total 144 pending office actions. The portfolio involves 50 distinct art units, suggesting a broad technical scope for the company's filings. KIM, YUNSOO is the busiest examiner, currently overseeing 4 pending office actions.
The 117 distinct examiners involved indicate that many examiners are responsible for more than one case for the company. This wide distribution across 50 distinct art units requires the company to manage diverse procedural requirements within Biotechnology & Pharmaceuticals. KIM, YUNSOO, with 4 pending office actions, holds a higher individual workload than the other distinct examiners. Practitioners should monitor the 144 pending office actions for consistency across the 50 distinct art units.
The 50 distinct art units represent a significant range of technical examination standards that the company must meet. With 144 pending office actions, the volume of work is substantial relative to the 4 pending office actions assigned to KIM, YUNSOO. Understanding the specific preferences of the 117 distinct examiners is crucial for successful prosecution across the portfolio.
Based on the USPTO statutory response window for each pending office action. 37 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 37 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (1%) |
| §101 + other | 20 (14%) |
| §103 only | 28 (19%) |
| §102 only | 3 (2%) |
| §112 only | 26 (18%) |
| Double-patenting only | 3 (2%) |
| Double-patenting + other | 24 (17%) |
| Multi-statute (no §101) | 34 (23%) |
| No statute on record | 6 (4%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, YUNSOO | 4 | 65.9% | +34.2% |
| WILSON, MICHAEL C | 4 | 41.6% | +17.9% |
| HOWARD, ZACHARY C | 3 | 63.9% | +37.6% |
| STONEBRAKER, ALYSSA RAE | 3 | 58.2% | +50.0% |
| XU, XIAOYUN | 3 | 60.0% | +31.8% |
| LI, RUIXIANG | 2 | 59.4% | +18.7% |
| WEHBE, ANNE MARIE SABRINA | 2 | 57.2% | +43.4% |
| ROONEY, NORA MAUREEN | 2 | 60.4% | +23.5% |
| SAOUD, CHRISTINE J | 2 | 57.9% | +37.4% |
| FRITCHMAN, REBECCA M | 2 | 45.7% | +35.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18130980 | COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST | HOWARD, ZACHARY C | 127d overdue |
| 18336148 | SYSTEMS AND METHODS FOR DRUG DELIVERY TO OCULAR TISSUE | MEDWAY, SCOTT J | 25d overdue |
| 17954999 | ASSAYS TO QUANTITATE DRUG AND TARGET CONCENTRATIONS | EVANS, CHRISTOPHER RYAN | 4d overdue |
| 17041252 | GENETICALLY MODIFIED NON-HUMAN ANIMALS FOR GENERATING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS OF MAKING AND USES THEREOF | WILSON, MICHAEL C | 4d overdue |
| 18187564 | PRECISION DOSE DELIVERY DEVICE PLUNGER ROD INSERTION GAUGE AND METHODS THEREFOR | NGUYEN, ANDREW H | 2d overdue |
| 17433887 | ADENO-ASSOCIATED VIRUS VECTORS FOR THE DELIVERY OF THERAPEUTICS | LEONARD, ARTHUR S | 6d |
| 17356497 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | CANELLA, KAREN A | 8d |
| 17885805 | MASS SPECTROMETRY-BASED STRATEGY FOR DETERMINING PRODUCT-RELATED VARIANTS OF A BIOLOGIC | WHITE, ASHLEY TAYLOR | 13d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18130980 | COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST | HOWARD, ZACHARY C | 127d overdue |
| 17684674 | SYSTEMS AND METHODS FOR QUANTIFYING AND MODIFYING PROTEIN VISCOSITY | XU, XIAOYUN | 31d overdue |
| 17041252 | GENETICALLY MODIFIED NON-HUMAN ANIMALS FOR GENERATING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS OF MAKING AND USES THEREOF | WILSON, MICHAEL C | 4d overdue |
| 19248893 | METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREBY | KIM, YUNSOO | 8d |
| 19333264 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | LI, RUIXIANG | 43d |
| 17870368 | NATIVE MICROFLUIDIC CE-MS ANALYSIS OF ANTIBODY CHARGE HETEROGENEITY | XU, XIAOYUN | 55d |
| 19217541 | PROCESS FOR REDUCING SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION | KIM, YUNSOO | — |
| 18999448 | COMPOSITIONS AND METHODS FOR EXPRESSING FACTOR IX | WEHBE, ANNE MARIE SABRINA | — |
| Art Unit | Apps |
|---|---|
| 1642 | 8 |
| 1641 | 7 |
| 1675 | 7 |
| 1643 | 7 |
| 1674 | 6 |
| 1637 | 6 |
| 1634 | 6 |
| 1638 | 5 |
| 1636 | 4 |
| 1631 | 4 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19333578 | DEVICES AND METHODS FOR OVERFILLING DRUG CONTAINERS | SHRIEVES, STEPHANIE ALEXANDRA | 3753 | DP | Non-Final OA | — | Pending | Sep 19, 2025 |
| 19333264 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | LI, RUIXIANG | 1674 | §103 | Non-Final OA | 43d | Pending | Sep 18, 2025 |
| 19248893 | METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREBY | KIM, YUNSOO | 1641 | §112DP | Non-Final OA | 8d | Pending | Jun 25, 2025 |
| 19217541 | PROCESS FOR REDUCING SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION | KIM, YUNSOO | 1641 | §102DP | Non-Final OA | — | Pending | May 23, 2025 |
| 19057507 | MICROCHIP CAPILLARY ELECTROPHORESIS ASSAYS AND REAGENTS | BALL, JOHN C | 1795 | §103§112Other | Non-Final OA | — | Pending | Feb 19, 2025 |
| 19024513 | VEGF-TRAP PROTEIN VARIANTS AND ANALYSIS THEREOF | SUN, CAITLYN MINGYUN | — | §103 | Non-Final OA | — | Pending | Jan 16, 2025 |
| 18999448 | COMPOSITIONS AND METHODS FOR EXPRESSING FACTOR IX | WEHBE, ANNE MARIE SABRINA | — | §103§112DP | Non-Final OA | — | Pending | Dec 23, 2024 |
| 18945863 | SYSTEMS AND METHODS FOR PRODUCING SMALL-SCALE MIXERS FOR DRUG MANUFACTURING | PATEL, VISHAL I | 1746 | §103 | Non-Final OA | — | Pending | Nov 13, 2024 |
| 18942224 | ASPARAGINE FEED STRATEGIES TO IMPROVE CELL CULTURE PERFORMANCE AND MITIGATE ASPARAGINE SEQUENCE VARIANTS | SINGH, SATYENDRA K | — | §103 | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18830643 | ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF | BOESEN, AGNIESZKA | — | §112 | Non-Final OA | — | Pending | Sep 11, 2024 |
| 18802201 | NON-HUMAN ANIMALS HAVING A HUMANIZED LYMPHOCYTE-ACTIVATION GENE 3 | WRIGHT, ERIC BRANDON | — | §112 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18798198 | Treatment Of Hyperglycemia With Solute Carrier Family 39 Member 5 (SLC39A5) Inhibitors | KONOPKA, CATHERINE ANNE | 1635 | §103§112DP | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18785975 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | RICCI, CRAIG D | 1611 | §102§112Other | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18786335 | METHODOLOGY TO CHARACTERIZE EMPTY-FULL RATIO IN CRUDE AAV SAMPLES | GILL, RACHEL B | — | §102§103§112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18777757 | SYSTEMS AND METHODS FOR MOTOR ASSESSMENT | EDWARDS, ETHAN WESLEY | — | §101§103 | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18776820 | METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST | HOWARD, ZACHARY C | 1674 | Other | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18763265 | METHODS FOR MITIGATING DRUG TARGET INTERFERENCE IN AN ANTI-DRUG ANTIBODY (ADA) IMMUNOASSAY | HAQ, SHAFIQUL | — | §103§112DP | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18763490 | METHODS AND COMPOSITIONS FOR MODIFYING A TARGETED LOCUS | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18721743 | NON-HUMAN ANIMALS COMPRISING HUMANIZED ACE2 AND TMPRSS LOCI | GRABER, JAMES J | — | §101§102§103§112DP | Non-Final OA | — | Pending | Jun 19, 2024 |
| 18734482 | LOW AFFINITY FcyR DEFICIENT MICE | WILSON, MICHAEL C | 1638 | §112Other | Non-Final OA | — | Pending | Jun 05, 2024 |
| 18674399 | METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS | HOWARD, ZACHARY C | 1674 | §112Other | Non-Final OA | — | Pending | May 24, 2024 |
| 18670314 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | LU, CHENG | 1642 | §103DP | Non-Final OA | — | Pending | May 21, 2024 |
| 18670684 | Chimeric Antigen Receptors with BCMA Specificity and Uses Thereof | BURKHART, MICHAEL D | — | — | Non-Final OA | — | Pending | May 21, 2024 |
| 18669172 | Anti-CTLA-4 Antibodies and Uses Thereof | ROONEY, NORA MAUREEN | — | §112DP | Non-Final OA | — | Pending | May 20, 2024 |
| 18659538 | SYSTEMS AND METHODS FOR REDUCING SAMPLE SIZES | ERICKSON, BENNETT S | 3683 | §101§103 | Non-Final OA | — | Pending | May 09, 2024 |
| 18707263 | NON-HUMAN ANIMALS COMPRISING A MODIFIED CACNG1 LOCUS | MIANO, JOSEPH PAUL | — | §101§102§103 | Non-Final OA | — | Pending | May 03, 2024 |
| 18647109 | METHODS FOR CHARACTERIZING LOW-ABUNDANCE HOST CELL PROTEINS | CHIN, CHRISTOPHER L | 1677 | §101 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18645694 | METHODS FOR SELECTING EXCIPIENTS AND FOR PREPARING HIGH CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS AND OTHER FORMULATIONS COMPRISING PROTEINS | SAOUD, CHRISTINE J | — | §102§103§112 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18637055 | CONCENTRATION-DEPENDENT SELF-INTERACTION ASSAY | NGUYEN, NAM P | — | §102§103§112 | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18634633 | SYSTEMS, METHODS, AND APPARATUSES FOR IMPROVED INSTRUMENT MONITORING AND ANALYTICS | MINCEY, JERMAINE A | — | §101§102§103 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18699454 | STEREOCILIN PROMOTERS AND USES THEREOF | MOLOYE, TITILAYO | — | — | Non-Final OA | — | Pending | Apr 08, 2024 |
| 18610188 | COMBINATION OF IL-4/IL-13 PATHWAY INHIBITORS AND PLASMA CELL ABALATION FOR TREATING ALLERGY | CHANDRA, GYAN | — | §112 | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18606302 | Proteomic Risk Score For Osteoarthritis (OA) | FRITCHMAN, REBECCA M | — | §101§103§112 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18604573 | METHODS FOR OBTAINING ANTIBODY MOLECULES WITH HIGH AFFINITY | MARCSISIN, ELLEN JEAN | — | §103§112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18592388 | ANTI-FEL D1 ANTIBODY FORMULATIONS | KIM, YUNSOO | — | §103DP | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18589384 | MULTIVALENT ANTI-SPIKE PROTEIN BINDING MOLECULES AND USES THEREOF | METCALF, MATTHEW CURRAN | — | §102§103DP | Non-Final OA | — | Pending | Feb 27, 2024 |
| 18582159 | Treatment Of Obesity In Subjects Having Variant Nucleic Acid Molecules Encoding Calcitonin Receptor (CALCR) | KAPUSHOC, STEPHEN THOMAS | 1683 | §112DP | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18436306 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | GONZALEZ, LUISALBERTO | 1624 | §112 | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18432780 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | LI, RUIXIANG | — | §112Other | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18421538 | CHARACTERIZATION OF SERINE-LYSINE CROSS-LINK IN ANTIBODY HIGH MOLECULAR WEIGHT SPECIES | COLE, HOUSTON DAVID | — | §101§102§103§112 | Non-Final OA | — | Pending | Jan 24, 2024 |
| 18580810 | IL12 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | ALLEN, MARIANNE P | — | §112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18543857 | HUMAN LAMBDA LIGHT CHAIN MICE | WILSON, MICHAEL C | 1638 | §112DP | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18535105 | Treatment Of Prion Diseases | ZARA, JANE J | 4100 | §103§112 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18535052 | Treatment Of Type 2 Diabetes With Hepatocyte Nuclear Factor 4 Alpha (HNF4A) Agonists | PERSONS, JENNA L | 4100 | §112 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18528268 | METHODS TO CHARACTERIZING A FRAGMENT CRYSTALLIZABLE DOMAIN OF A BISPECIFIC ANTIBODY | RAMADAN, OMAR | 1678 | §102§103§112 | Non-Final OA | — | Pending | Dec 04, 2023 |
| 18514880 | CELL CULTURE MEDIUM FOR EUKARYOTIC CELLS | KIM, TAEYOON | 1631 | §103§112DP | Final Rejection | 35d | Pending | Nov 20, 2023 |
| 18512259 | DUAL-COLOR FLUORESCENCE CROSS-CORRELATION SPECTROSCOPY | SINES, BRIAN J | 1796 | §102§103§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18510900 | Treatment Of Inflammation With Glucocorticoids And Angiopoietin-Like 7 (ANGPTL7) Inhibitors | HUDSON, AMY ROSE | 1636 | §103§112DP | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18509030 | COMPOSITIONS AND METHODS FOR FIBROBLAST GROWTH FACTOR RECEPTOR 3-MEDIATED DELIVERY TO ASTROCYTES | HUYNH, PHUONG N | 1641 | §112DP | Non-Final OA | — | Pending | Nov 14, 2023 |
| 18509136 | ANTI-FGFR3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS AND METHODS OF USE THEREOF | BENAVIDES, JENNIFER ANN | 1675 | §112Other | Non-Final OA | — | Pending | Nov 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRegeneron Pharmaceuticals Inc. has 145 pending office actions as of October 2026, spread across 49 art units and 116 examiners.
Yunsoo Kim has the most, with 4 of Regeneron Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.